Neurotrope: Charles Ryan
Charles Ryan has been appointed CEO of neurodegenerative disease-focused Neurotrope.
Ryan – who will start at Neurotrope on February 15 – previously held a variety of positions in the Alzheimer’s disease space, including as senior vice president and chief intellectual property counsel at Forest Laboratories.
Ryan is president and CEO of Orthobond Corporation, and has served as vice president, general counsel for Cold Spring Harbor Laboratory.
He holds a BA in Chemistry from The College of Wooster, a PhD in Oral Biology and Pathology from Stony Brook University and a JD from Western New England University.
Ryan said the fundamental science behind Neurotrope’s lead candidate – bryostatin – is solid.
“The compound’s unique mechanism of action represents one of the most promising therapeutic approaches to not only slow cognitive decline, but actually improve cognition in patients with advanced Alzheimer’s disease,” he said.
“As a first step, Neurotrope will conduct an additional study to confirm the findings in the exploratory trial with bryostatin in advanced Alzheimer’s disease, and then advance the therapeutic for possible approval to address this major unmet medical need,” he told us.
Holiday plans?
“In addition to getting better acquainted with my new colleagues at Neurotrope, I look forward to spending the holidays in Princeton and New York City with my family, including my brothers, their spouses and their children,” Ryan told us.